バージニアにおける慢性リンパ性白血病の臨床試験
バージニア内の拠点で、慢性リンパ性白血病に関する12件の研究が参加者を募集しています。
バージニア内の都市
公式研究テキスト（英語）
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- VCU Massey Comprehensive Cancer Center, Richmond
- VCU Health Tappahannock Hospital, Tappahannock
被験者募集中第3相
65歳以上 · 全性別 · 2026/10/02更新 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Chesapeake Regional Medical Center, Chesapeake
- Augusta Health Center for Cancer and Blood Disorders, Fishersville
- Bon Secours Memorial Regional Medical Center, Mechanicsville
- 他7件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Ballad Health Cancer Care - Bristol, Bristol
- Ballad Health Cancer Care - Norton, Norton
- VCU Massey Cancer Center at Stony Point, Richmond
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT04269902A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Virginia Commonwealth University Massey Cancer Center, Richmond
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05006716A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Blue Ridge Cancer Care (Oncology and Hematology Associates of Southwest Virginia), Roanake
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT06973187A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- University of Virginia Cancer Center ( Site 5402), Charlottesville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/24更新 · NCT05947851A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- University of Virginia Cancer Center ( Site 0040), Charlottesville
- Inova Schar Cancer Institute ( Site 0015), Fairfax
- Virginia Commonwealth University (VCU) Medical Center ( Site 0030), Richmond
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06136559A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Virginia Cancer Specialists, PC, Fairfax
- Oncology & Hematology Associates of Southwest VA, Norfolk
- Virginia Oncology Associates, Norfolk
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07221500Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
- Virginia Cancer Specialists, Fairfax
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/31更新 · NCT07516093A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Virginia Cancer Institute, Richmond
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05254743A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- USO-Virginia Oncology Associates, Hampton
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/19更新 · NCT06588478A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Virginia Cancer Specialists - Fairfax /ID# 268155, Fairfax
被験者募集中第3相
18歳以上 · 全性別 · 2026/04/09更新 · NCT06428019ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。